Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase

被引：3
|
作者：
Dees, E. [1 ]
Infante, J. R. [2 ]
Cohen, R. B. [3 ]
O'Neil, B. [1 ]
Burris, H. [2 ]
von Mehren, M. [3 ]
Gray, G. [4 ]
Galvin, K. [5 ]
Manfredi, M. [5 ]
Eton, O. [6 ]
机构：
[1] UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[4] Millennium Pharmaceut Inc, Drug Dev, Cambridge, MA USA
[5] Millennium Pharmaceut Inc, Canc Pharmacol, Cambridge, MA USA
[6] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72215-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：91 / 91
页数：1
相关论文
共 50 条
  • [21] Effect of aurora A inhibition in cultured human tumor cells using the selective small molecule inhibitor MLN8054
    Ecsedy, Jeffrey A.
    Hoar, Kara
    Wysong, Deborah R.
    Rabino, Claudia
    Bowman, Douglas S.
    Chakravarty, Arijit
    Roy, Natalie
    CANCER RESEARCH, 2006, 66 (08)
  • [22] MLN8054, an orally active small molecule inhibitor, mediates tumor growth inhibition in vivo through Aurora A kinase.
    Burenkova, O
    Bond, S
    Connolly, K
    Galvin, K
    Huck, J
    Manfredi, M
    Stringer, B
    Zhang, MK
    Meetze, K
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9082S - 9082S
  • [23] MLN8054 selectively inhibits Aurora A over Aurora B in cultured human tumor cells.
    Hoar, KM
    Wysong, DR
    Ecsedy, JA
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9109S - 9109S
  • [24] Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237
    Sloane, Dominic A.
    Trikic, Michael Z.
    Chu, Matthew L. H.
    Lamers, Maria B. A. C.
    Mason, Clive S.
    Mueller, Ilka
    Savory, Wendy J.
    Williams, David H.
    Eyers, Patrick A.
    ACS CHEMICAL BIOLOGY, 2010, 5 (06) : 563 - 576
  • [25] Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
    Cervantes, Andres
    Elez, Elena
    Roda, Desamparados
    Ecsedy, Jeffrey
    Macarulla, Teresa
    Venkatakrishnan, Karthik
    Rosello, Susana
    Andreu, Jordi
    Jung, JungAh
    Sanchis-Garcia, Juan Manuel
    Piera, Adelaida
    Blasco, Inma
    Manos, Laura
    Perez-Fidalgo, Jose-Alejandro
    Fingert, Howard
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4764 - 4774
  • [26] MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy
    Hoar, Kara
    Chakravarty, Arijit
    Rabino, Claudia
    Wysong, Deborah
    Bowman, Douglas
    Roy, Natalie
    Ecsedy, Jeffrey A.
    MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (12) : 4513 - 4525
  • [27] MLN8237, an oral selective Aurora A kinase inhibitor: initial results of dose-finding pharmacokinetic-pharmacodynamic phase I study
    Tabernero-Caturla, J.
    Cervantes, A.
    Elez, E.
    Macarulla, T.
    Rosello, S.
    Rodriguez-Braun, E.
    Stringer, B.
    Shinde, V.
    Danaee, H.
    Eton, O.
    EJC SUPPLEMENTS, 2008, 6 (12): : 92 - 92
  • [28] MLN8054, an Aurora A kinase inhibitor, inhibits proliferation of cultured human tumor cells by p53-dependent and p53-independent mechanisms.
    LeRoy, PJ
    Wysong, DR
    Hoar, KM
    Ecsedy, JA
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9108S - 9108S
  • [29] A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Consortium study.
    Mosse, Y. P.
    Lipsitz, E. G.
    Maris, J. M.
    Weigel, B.
    Adamson, P. C.
    Ingle, M.
    Ahern, C. H.
    Blaney, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora kinase inhibitor GSK1070916A.
    McNeish, Iain
    Anthoney, Alan
    Loadman, Paul
    Berney, Dan
    Joel, Simon
    Halford, Sarah E. R.
    Buxton, Emily
    Race, Amanda
    Ikram, Mohammed
    Scarsbrook, Andrew
    Patikis, Angela
    Rockall, Andrea
    Dobbs, Nicola A.
    Twelves, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345